Fadeucravacitinib vs HS-10374

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Fadeucravacitinib

Developed by Beijing InnoCare Pharma Tech Co.

Phase 3 in Psoriasissmall molecule
Partial signal

NCT06109818 · Phase 2 · completed

The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.

Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12. (Baseline up to Week 12): PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved (met)

Result source: NCT06109818

HS-10374

Developed by Hansoh Pharmaceutical Group

Phase 3 in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFadeucravacitinibHS-10374
PASI 75—Trial running · NCT06842199—Trial running · NCT06672393
PASI 90—Trial running · NCT06842199—Trial running · NCT06672393
PASI 100—Trial running · NCT06842199—Trial running · NCT06672393
sPGA 0/1—Trial running · NCT06842199—Trial running · NCT06672393
DLQI, change—Trial running · NCT06842199—Trial running · NCT06672393

PASI 75

Fadeucravacitinib
—Trial running · NCT06842199
HS-10374
—Trial running · NCT06672393

PASI 90

Fadeucravacitinib
—Trial running · NCT06842199
HS-10374
—Trial running · NCT06672393

PASI 100

Fadeucravacitinib
—Trial running · NCT06842199
HS-10374
—Trial running · NCT06672393

sPGA 0/1

Fadeucravacitinib
—Trial running · NCT06842199
HS-10374
—Trial running · NCT06672393

DLQI, change

Fadeucravacitinib
—Trial running · NCT06842199
HS-10374
—Trial running · NCT06672393
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HS-10374: no structured comparison results are available for Psoriasis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Fadeucravacitinib
PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved NCT06109818 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fadeucravacitinib's landscape · HS-10374's landscape